{"Clinical Trial ID": "NCT00950742", "Intervention": ["INTERVENTION 1:", "Afatinib 20mg + Herceptin", "Patients received a continuous daily dose of Afatinib 20mg film-coated tablets and once weekly an intravenous infusion of Herceptin until disease progression or no clinical benefit.", "INTERVENTION 2:", "Afatinib 30mg + Herceptin", "Patients received a continuous daily dose of Afatinib 30 mg film-coated tablets and once weekly an intravenous infusion of Herceptin until disease progression or no clinical benefit."], "Eligibility": ["\u2022 Inclusion criteria:", "Women over 18 years of age.", "Prior treatment with Herceptin\u00ae or Lapatinib\u00ae (under adjuvant or metastatic conditions) is permitted but not required.", "- Exclusion criteria:", "\u00b7 Prior treatment with EGFR targeting EGFR- or HER2- or EGFR- or HER2- or EGFR- or HER2- or EGFR- or HER2- or EGFR- or HER2- or EGFR- or HER2- or EGFR- or EGFR- or HER2- or EGFR- or HER2- or EGFR- or EGFR- or HER2- or EGFR- or HER2- or EGFR- or HER2- or EGFR- or HER2- or EGFR- or HER2- or EGFR- or HER2- or EGFR- or EGFR- or EGFR- or HER2- or EGFR- or EGFR- or HER2- or EGFR- or HER- or EGFR- or HER2- or EGFR- or HER2- or EGFR- or HER2- or HER- or HER-2- or EGFR- or EGFR- or HER- or HER- or HER-2- or EGFR- or EGFR- or EGFR- or EGFR- or EGFR-EGFR- or EGFR- or HER-EGFR- or HER-EGFR- or EGFR- or EGFR- or HER-EG- or HER- or HER-EGFR-EG-EGFR- or HER-EG-EG- or EGFR-EG."], "Results": ["Performance measures:", "Number of participants with a Toxic Limit Dose (DLT)", "Number of participants with a DLT during the first cycle (28 days) for the determination of the maximum tolerated dose (LDT).", "Time limit: 28 days", "Results 1:", "Title of arm/group: Afatinib 20mg + Herceptin", "Description arm/group: Patients received a continuous daily dose of Afatinib 20mg film-coated tablets and once weekly an intravenous infusion of Herceptin until disease progression or no clinical benefit.", "Total number of participants analysed: 13", "Type of measurement: Number", "Unit of measure: Participants 4", "Results 2:", "Title of arm/group: Afatinib 30mg + Herceptin", "Description arm/group: Patients received a continuous daily dose of Afatinib 30mg film-coated tablets and once weekly an intravenous infusion of Herceptin until disease progression or no clinical benefit.", "Total number of participants analysed: 2", "Type of measurement: Number", "Unit of measure: Participants 2"], "Adverse Events": ["Undesirable Events 1:", "Total: 3/16 (18.75 per cent)", "Diarrhoea 1/16 (6.25 per cent)", "Acute renal impairment 1/16 (6.25 per cent)", "1/16 (6.25%)", "Adverse Events 2:", "Total: 0/2 (0.00 per cent)", "Diarrhoea 0/2 (0.00 %)", "Acute renal impairment 0/2 (0.00 %)", "- Pulmonary embolism 0/2 (0.00 %)"]}